期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 61, 期 6, 页码 2353-2371出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.7b01612
关键词
-
资金
- National Natural Science Foundation of China [21572230, 81425021, 81673285]
- Guangdong Province [2014TQ01R341, 2015A030306042, 2015A030312014, 2016A050502041]
- Guangzhou City [201508030036]
- Jinan University
Colony stimulating factor 1 receptor kinase (CSF1R) is a well validated molecular target for anticancer drug discovery. Herein, we report the design, synthesis, and structure activity relationship study of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as new orally bioavailable CSF1R inhibitors. One of the most promising compounds, 3bw, potently inhibits CSF1R kinase with an IC50 value of 3.0 nM, while it is less potent against structurally related epidermal growth factor receptor (EGFR) and other kinases. The kinase inhibition of 3bw was further validated by Western blotting analysis in RAW264.7 macrophages. The molecule also potently blocks macrophage infiltration, abrogates the protumorigenic influences of macrophages, and exhibits reasonable pharmacokinetic profile. Compound 3bw may serve as a new valuable lead compound for future anticancer drug discovery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据